New pill aims to ease fatigue in rare mitochondrial disease
NCT ID NCT07514338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is for people who completed a previous trial of KL1333 (napazimone) for primary mitochondrial disease. It will test the drug's long-term safety and whether it helps with fatigue and daily activities. About 140 participants will take the pill twice daily for an extended period. The goal is to see if KL1333 can be a safe, long-term treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KL1333 (napazimone) taken as a pill twice daily
- What this could lead to
- If it works, this could offer a long-term treatment option to reduce fatigue and improve daily living for people with primary mitochondrial disease.
- What could go wrong
- This is an early-phase extension study with no placebo group, so results may not prove effectiveness. Side effects or tolerability issues could limit its use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MITOCHONDRIAL DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Worldwide data pool could pave the way for mitochondrial disease trials
- Scientists probe immune cell shifts in ICU patients to unlock sepsis secrets
- New study tests workplace coaching to keep Parkinson's patients on the job
- Massive genetic study aims to unlock secrets of rare metabolic diseases
- New study seeks to uncover hidden biological clues in kids with autism
- New model aims to speed up rare disease diagnosis